Saitama, Japan

Hiroshi Oinuma

This inventor holds 1 USPTO granted patent. Top assignees: Agency of Industrial Science and Technology, Sumitomo Electric Industries, Limited, Watanabe Pharmaceutical Industry Co., Ltd.. Active years: 1991.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 219(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroshi Oinuma: Innovator in Antithrombogenic Materials

Introduction

Hiroshi Oinuma is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of biomedical materials, particularly in the development of antithrombogenic materials. His innovative work has implications for medical devices and treatments.

Latest Patents

Hiroshi Oinuma holds a patent for an antithrombogenic material. This material comprises an expanded polytetrafluoroethylene base with a collagen layer on its surface. Additionally, it features a composite layer of collagen and a mucopolysaccharide, with the collagen crosslinked using a crosslinking agent. This invention aims to improve the performance of medical devices by reducing thrombosis.

Career Highlights

Throughout his career, Oinuma has worked with various organizations, including Watanabe Pharmaceutical Industry Co., Ltd. and the Agency of Industrial Science and Technology. His experience in these institutions has allowed him to refine his expertise in material science and biomedical applications.

Collaborations

Hiroshi Oinuma has collaborated with notable colleagues such as Makoto Kodama and Shigeru Asako. These partnerships have contributed to the advancement of his research and the successful development of innovative materials.

Conclusion

Hiroshi Oinuma's work in antithrombogenic materials showcases his dedication to improving medical technology. His contributions are vital for the advancement of safer and more effective medical devices.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…